D. Stojdl

发表

Going viral with cancer immunotherapy

C. Breitbach, J. Bell, B. Lichty, 2014, Nature Reviews Cancer.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

Nahum Sonenberg, H. Atkins, N. Sonenberg, 2000, Nature Medicine.

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

H. Atkins, D. Kirn, C. Breitbach, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

R. Paules, D. Ron, J. Bell, 2003, Molecular cell.

Characterization of Transgenic Mice with Targeted Disruption of the Catalytic Domain of the Double-stranded RNA-dependent Protein Kinase, PKR*

H. Atkins, N. Sonenberg, B. Vanderhyden, 1999, The Journal of Biological Chemistry.

Maraba virus as a potent oncolytic vaccine vector.

Liang Zhang, B. Lichty, D. Stojdl, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

A. Makrigiannis, L. Tai, J. Bell, 2017, Cancer Immunology Research.

SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds

S. Baird, R. Korneluk, D. Stojdl, 2011, Cell Death and Disease.

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

H. Atkins, D. Roy, J. Bell, 2015, Journal of controlled release : official journal of the Controlled Release Society.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

H. Atkins, J. Hiscott, J. Bell, 2003, Cancer cell.

Vesicular stomatitis virus: re-inventing the bullet.

J. Bell, B. Lichty, D. Stojdl, 2004, Trends in molecular medicine.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis

H. Atkins, J. Diallo, B. Vanderhyden, 2008, Proceedings of the National Academy of Sciences.

Codelivery of mRNA with α-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration

D. Stojdl, S. Persano, M. Guevara, 2019, ACS omega.

Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses

D. Mahoney, D. Stojdl, 2012, Clinical Cancer Research.

Model-based rational design of an oncolytic virus with improved therapeutic potential

Mads Kærn, H. Atkins, J. Diallo, 2013, Nature Communications.

Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy.

D. Mahoney, D. Stojdl, 2012, Future oncology.

Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum

D. Mahoney, T. Falls, D. Stojdl, 2013, International journal of cancer.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

J. Diallo, D. Roy, J. Bell, 2018, Science Translational Medicine.

Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

H. Atkins, J. Bell, K. Hu, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

U. Dietrich, L. Stubbert, J. Bell, 2014, Cancer research.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy

F. Saad, R. Breau, F. Tzelepis, 2018, Oncoimmunology.

Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells.

S. Beausoleil, J. Charron, J. Bell, 2001, Virus research.

Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy

S. Swift, D. Stojdl, 2016, Viruses.

Development and applications of oncolytic Maraba virus vaccines

J. Diallo, C. Breitbach, J. Bell, 2018, Oncolytic virotherapy.

Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

J. van Grevenynghe, J. Hiscott, Jian Hui Wu, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.

T. Alain, S. Baird, R. Al-awar, 2011, Cancer cell.

Oncolytic viruses: programmable tumour hunters.

J. Bell, K. Garson, B. Lichty, 2002, Current gene therapy.

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

D. Roy, J. Bell, B. Lichty, 2021, Nature Communications.

Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide

C. Nutt, J. Bell, D. Stojdl, 2009, Clinical Cancer Research.

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer

J. Diallo, Stephen Boulton, L. Pikor, 2022, Frontiers in Immunology.

Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain

S. Swift, D. Stojdl, C. Lefebvre, 2017, Molecular therapy oncolytics.

SR protein kinases: the splice of life.

J. Bell, D. Stojdl, J C Bell, 1999, Biochemistry and cell biology = Biochimie et biologie cellulaire.

The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus

N. Sonenberg, J. Bell, E. Brown, 2000, Journal of Virology.

Functional genomic screening to enhance oncolytic virotherapy

D. Mahoney, D. Stojdl, 2012, British Journal of Cancer.

In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase

J. Bell, D. Stojdl, R. Marius, 1997, Molecular and cellular biology.

Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity

J. Bell, D. Stojdl, J. Bramson, 2018, The Journal of clinical investigation.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

H. Atkins, J. Diallo, M. Burdick, 2015, Nature Medicine.

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

H. Atkins, J. Bell, Kelley A. Parato, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

High-throughput screening to enhance oncolytic virus immunotherapy

D. Stojdl, K. Allan, SL Swift, 2016, Oncolytic virotherapy.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

G. Stoll, G. Denisova, C. Breitbach, 2018, Oncoimmunology.

The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.

M. Jaramillo, N. Méthot, G. Barber, 1998, Experimental cell research.

Getting oncolytic virus therapies off the ground.

J. Bell, B. Lichty, D. Stojdl, 2003, Cancer cell.

The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing.

J. Bell, D. Stojdl, R. Marius, 1998, Experimental cell research.

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model

R. Korneluk, M. Holcik, Thet Naing, 2016, Oncotarget.

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.

H. Atkins, J. Bell, L. Miller, 2004, Human gene therapy.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

H. Atkins, J. Diallo, B. Vanderhyden, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Treatment of permissive tumors with the oncolytic virus ( OV ) VSV-Δ 51 leads to a robust antitumor

H. Atkins, J. Diallo, B. Vanderhyden, 2012 .

Customized Viral Immunotherapy for HPV-Associated Cancer

J. Diallo, S. Johnson-Obaseki, Fuan Wang, 2017, Cancer Immunology Research.

A call to arms: using RNAi screening to improve oncolytic viral therapy.

D. Mahoney, D. Stojdl, 2010, Cytokine & growth factor reviews.

Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis

G. McFadden, J. Barrett, J. Bell, 2015, Molecular therapy oncolytics.

Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential

J. Barrett, J. Bell, D. Stojdl, 2017, BMC Cancer.

Vesiculovirus Neutralization by Natural IgM and Complement

S. Russell, G. Barber, K. Peng, 2014, Journal of Virology.

Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development

D. Stojdl, D. Mealiea, T. Ho, 2021, Molecular therapy oncolytics.

Potentiating oncolytic viruses by targeted drug intervention.

D. Mahoney, D. Stojdl, 2010, Current opinion in molecular therapeutics.

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

A. Makrigiannis, L. Tai, J. Bell, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation

N. Sonenberg, J. Hiscott, J. Bell, 2008, Journal of Virology.

Trypanosoma brucei: analysis of cytoplasmic Ca2+ during differentiation of bloodstream stages in vitro.

D. Stojdl, M. Clarke, Michael W. Clarke, 1996, Experimental parasitology.

Characterizing Cellular Responses During Oncolytic Maraba Virus Infection

T. Alain, M. Holcik, D. Stojdl, 2019, International journal of molecular sciences.

Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein

S. Baird, M. Holcik, D. Stojdl, 2015, Cell Death and Disease.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

J. Lambris, L. Stubbert, J. Bell, 2016, Molecular therapy oncolytics.